←
timothy wand2,309 posts
timothy wand avatar

timothy wand

@timwand

Professor of nursing and nurse practitioner. Emergency mental health. Around the world in 80 years.

◷ Joined October 2011▧ 58 Photos and videos
The Telegraph avatar
⟳ timothy wand retweeted
The Telegraph@Telegraph·Nov 11

"I don’t just think antidepressants are overprescribed, I’m not convinced they’re useful at all. Antidepressants don’t rectify a chemical imbalance or any other biological process, as people were led to believe; they numb emotions" "The question is, is this useful, and how harmful are they?" 👇 telegraph.co.uk/health-fitne…

Post attachment
Mark Horowitz @markhoro.bsky.social avatar
⟳ timothy wand retweeted
Mark Horowitz @markhoro.bsky.social@markhoro·Nov 8

Jack has not permitted comments to be put on his blog so I’ll post this here. Many of the points in his blog are false. He has latterly corrected the quotation from our press release after I emailed him (although he does not disclose this was the reason for his correction). As he now acknowledges, we did not say what he had quoted us as saying and he has now corrected the quotation to say “this research calls into question reasonsfor the use of antidepressants.” Of course our paper calls into question the main rationale given to patients for prescribing these drugs – of course it calls the ‘reasons’ into question. He and others may wish to argue that the drugs are prescribed because they are effective (discussed at length elsewhere) but the rationale presented to many patients was (and is) false. Naturally, if it were found that Hashimoto’s disease was not caused by low thyroid hormones it would throw into question the rationale for prescribing thyroid hormones. It would throw into relief questions about long term harms and benefits of such a treatment that would not be raised if the treatment was acting in the self-evidently sensible manner of correcting a hormonal deficit. His central accusation – and the central point of his published article – is that we misleadingly presented our review regarding the aetiology of depression as showing that antidepressants are ineffective. We did not such thing. Jack could find no such quote in our press release so he fudged it. (I believe this is the polite euphemism). Of course such a finding about aetiology invites reflection on the efficacy of the drugs and so naturally we discussed this in the Conversation piece - our comments in this piece are all supported by evidence. His statement about the Nordic Cochrane is also false. Nordic Cochrane moved from Righospitalet in Copenhagen to the University of Southern Denmark in Odense where it merged with the Centre for Evidence-Based Medicine and was renamed to Cochrane Denmark. It still functions today and houses the Cochrane Bias Methods Group which advises Cochrane : cochrane.dk/ He is performing quite some somersaults, slinging mud from unrelated comments made by Peter Breggin, and Peter Gotzsche, to avoid reading an article published in the BMJ Open. An article I would still encourage him and other to read so that they become aware of the substantive criticisms of Cipriani’s meta-analysis rather than assuming the solidity of claims made about antidepressant efficacy: bmjopen.bmj.com/content/9/6/… I expect that after correcting his recent blog he will also correct his original blog on Awais’ website (where he falsely says: “a press release written by Moncrieff and co-author Mark Horowitz explicitly linked the umbrella review to a lack of efficacy in antidepressants”) and his academic paper were he makes the same false claim (“a press release written by Moncrieff and co-author Mark Horowitz explicitly linked the umbrella review to a lack of efficacy in antidepressants”) as he has now acknowledged that these claims are false. I would like to be notified when these corrections are made.

Thanks Mark, just posting my reply here. jocgoulder.substack.com/p/my…

Dr. Josef avatar
⟳ timothy wand retweeted
Dr. Josef@DrJosefWD·Oct 27

I'm a psychiatrist and a dad. There are 3 types of medications I'd be extremely cautious about giving my kids. Not because kids don't suffer. Because once you understand what these drugs do to a developing brain, you can't unsee it. 1. Antidepressants (Prozac, Zoloft, Lexapro) About 1 in 20 American kids take them. When the FDA looked at all the trial data, kids and young adults up to 25 had higher rates of suicidal thoughts and behaviors on the drug than on placebo. They're studied for 8 to 12 weeks, never beyond a year. Median real-world use is 5 years. And juvenile monkeys given Prozac had brain changes that didn't reverse years after the drug was removed. 2. ADHD meds (Adderall, Ritalin, Vyvanse) The youngest kids in a classroom are about 40% more likely to be prescribed them. We may be medicating immaturity. Stimulants don't improve academic performance. Kids just feel more confident about their work. The behavior benefits faded by about 3 years in the largest long-term study. And kids on them ended up about an inch shorter on average. 3. Antipsychotics (Abilify, Seroquel, Zyprexa) The ones that worry me most. In my experience, kids often end up on them to treat side effects of other drugs. In monkeys, they caused an 8 to 11% loss of frontal lobe volume. About 5% of patients a year develop tardive dyskinesia, involuntary face and mouth movements that can be permanent. I've seen people gain 50 to 100 pounds. What I'd do first: → Look at the home. Do therapy as a family. → Fix diet, sleep, movement and sunlight. US kids get about 60% of their calories from ultra-processed food. → For hyperactivity, try parent-child behavioral therapy. → If it isn't dangerous or severe, take a breath. Love them, stay present, and give it time. My message isn't never use medication. It's that this is a serious decision, so do the non-drug approaches first. If you're struggling, call or text 988 (US) or your local crisis line. Comment TAPER and I'll send you my free safe tapering guide.

Post attachment
Mad In America avatar
⟳ timothy wand retweeted
Mad In America@Mad_In_America·Oct 27

The Fonagy Report: A Missed Opportunity to Challenge the Neurodevelopmental Narrative By Joanna Moncrieff, MD An independent review in the UK to address ADHD and autism diagnosis and treatment has missed an opportunity to correct misleading notions. buff.ly/vbxHa0d

Post attachment
Dr Joanna Moncrieff avatar
⟳ timothy wand retweeted
Dr Joanna Moncrieff@joannamoncrieff·Oct 24

Uta Frith & @naomicfisher on the role of private providers in the expansion of ASD and ADHD diagnoses. People are incentivised to get diagnosis 'by a system that positions diagnosis as the key to services and self understanding'. ihttps://www.bmj.com/content/395/bmj-2026-101196

Adam Urato, MD avatar
⟳ timothy wand retweeted
Adam Urato, MD@AdamUrato1·Oct 4

These headlines are misleading. The strongest finding in this NEW STUDY is that children exposed to antidepressants in utero had the highest rates of Autism, ADHD, & behavioral-emotional-social difficulties. Nothing in this study shows that taking antidepressants lowers the risk of these outcomes. But the misleading headlines focus on depression rather than antidepressants. The media is failing to correctly inform the public. journals.plos.org/plosmedici…

Post attachment
Mad In America avatar
⟳ timothy wand retweeted
Mad In America@Mad_In_America·Sep 21

The long-awaited #ODDESSI trial - the first randomized controlled trial of Open Dialogue - has at last been published in The Lancet Psychiatry. The results provide a beginning for rethinking psychiatric care. buff.ly/Y63ol2C

Post attachment
Dr Joanna Moncrieff avatar
⟳ timothy wand retweeted
Dr Joanna Moncrieff@joannamoncrieff·Sep 20

Great coverage of why we should be concerned about the antidepressant epidemic: 'I hope that in the future people will realise that this huge experiment in medicalising our emotions and our life difficulties is a mistake'. gbnews.com/health/mental-hea…

Mark Horowitz @markhoro.bsky.social avatar
⟳ timothy wand retweeted
Mark Horowitz @markhoro.bsky.social@markhoro·Sep 4

Not very long so full text here: The importance of minimising long-term antidepressant use We recently argued that patients prescribed antidepressants should undergo regular review to consider whether continued prescribing or deprescribing is indicated.1 The evidence supporting continued treatment is flawed since discontinuation trials showing that continuation of antidepressants prevents relapse are likely to be confounded by withdrawal symptoms. This applies to the Geddes meta-analysis, mentioned by Looi et al,2 in which antidepressants were typically stopped abruptly or over only a few days. Such rapid discontinuation is well recognised to produce withdrawal symptoms that overlap with relapse measures, fundamentally undermining confidence in estimates of relapse prevention.3 Alongside doubtful evidence of benefit, there is clear evidence of harm with continuing antidepressants long term including emotional numbing, sexual dysfunction, weight gain, diabetes and, in older adults, increased risks of falls, fractures and possibly premature mortality. Looi et al agree that antidepressants should be reviewed regularly and discontinued when harms outweigh benefits. However, they do not address our central argument regarding the methodological limitations of discontinuation trials concerning their confounding by withdrawal symptoms. Looi et al also provide no evidence supporting their assertion that antidepressants remain beneficial for long-term treatment of recurrent moderate-to-severe depression. Long-term antidepressant use may only be beneficial in preventing withdrawal symptoms. Recent Australian data indicate that antidepressants are overwhelmingly prescribed by general practitioners (91%), unchanged from 2007 to 2011.4 Looi et al question whether evidence on antidepressant withdrawal symptoms from a UK National Health Service cohort is generalisable to Australia. There is no biological reason why withdrawal phenomena should differ between British and Australian patients. There is a growing body of international literature showing that patients can experience severe and prolonged withdrawal symptoms, particularly after long-term antidepressant use.5,6 Whether antidepressants should be continued long term and how to help patients who wish to stop taking antidepressants are important clinical questions. Reliable evidence supporting maintenance treatment is lacking, while there is evidence of harm.